AI-driven case intake benefits and key implementation considerations

Pharmacovigilance (PV) case intake is critical in adverse event (AE) reporting, ensuring compliance with global regulatory requirements and maintaining patient safety.

However, traditional case intake methods, which include receiving, transcribing and validating reports, have become increasingly unsustainable as regulatory expectations evolve and the volume of cases increase.

Despite optimism shown by some technology vendors that use artificial intelligence (AI), there is scant evidence of significant deployment of AI in real functioning pharmacovigilance systems over the years.

In this white paper, PPD Functional Service Partnership (FSP) Pharmacovigilance solutions experts:

• Re-examine the benefits of AI-assisted case intake and processing
• Discuss barriers to adoption of earlier systems and two key factors which have significantly reduced these barriers over the past four years
• Share five key implementation considerations